Business Wire

Mavenir Announces 5G Core Network and Cloud RAN Solutions Providing Full End-to-End 4G LTE and 5G Ready Networks

Share

Mavenir, the leader in accelerating and redefining software network transformation for Communications Service Providers, today announced its 5G Core Network and Cloud RAN solutions enabling Mavenir to be a full end-to-end 4G LTE and 5G, IoT network provider.

The 5G New Radio (NR) and the 5G Core element realization and deployment requirements are sharp departures from the traditional approaches of legacy vendors. Mavenir has these elements, supporting 4G LTE, already in trials and POCs in several countries.

“Mavenir is uniquely positioned to enable customers to evolve their networks and further the adoption of virtualization to maximize operational efficiency, network elasticity and Capex/Opex savings,” said Pardeep Kohli, President and CEO of Mavenir. “Operators can literally get a 5G network, using their 4G expansion budgets, with Mavenir’s 5G Ready vBBU which can be used together with any RRU.”

Mavenir’s 5G ready Cloud Native architecture is a fully virtualized, integrated service centric framework that is critical for highly granular scalability, elasticity, dynamic control, and orchestration for the entire network.

Mavenir’s 5G Core Network is designed for mobile communications systems with the functional capabilities to support high bandwidth, massive IoT connectivity and ultra-low latency applications. Highlights:

  • Cloud Native, fully virtualized, stateless architecture with a flexible End-to-End orchestration framework to suit varied CSP needs.
  • SDN-controlled 5GC with complete separation of both Control and User Plane framework that allows independent dynamic scaling of control and user plane elements with intelligent packet handling.

Mavenir’s Cloud RAN extends the virtualization to the edge of the network and provides strategic differentiation by enabling the Remote Radio Units (RRUs) to interwork with the virtualized Cloud Base Band Unit (vBBU) over ethernet Fronthaul (FH), overcoming the traditional constraints of Common Public Radio Interface (CPRI™) over fiber. Highlights:

  • With End-to-End network slicing support, flexibility for the vBBU and even the vEPC co-located for Multi-access Edge Computing (MEC) – the solution can be tailored for unique service centric architectures, enriching user experience while addressing proximity specific deployments constraints.
  • Investment protection is achieved (e.g. 4G LTE to 5G NR) through remote-upgradable Software Defined Radio (SDR) capabilities.

Added Kohli, “At this point, any CSP that is continuing to spend Capex on proprietary hardware radio, is going down a dead end.”

Both Mavenir’s access and core offerings, are enabled by its network functions virtualization (NFV) and container management and orchestration platform called CloudRange™.

About Mavenir:

Mavenir is a leader in accelerating and redefining network transformation for Service Providers, by offering a comprehensive product portfolio across every layer of the network infrastructure stack. From 4G to 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.

Through its industry first VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, Visual Voicemail and Cloud RAN solutions, and serving 350+ CSPs across 3.5 billion subscribers, Mavenir’s platform enables Service Providers to successfully deliver next generation vision today and realize new revenue streams and operational efficiencies. www.mavenir.com.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2017 Mavenir Systems, Inc. All Rights Reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Mavenir
Maryvonne Tubb
VP, Marketing
pr@mavenir.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye